Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q8NDX2
UPID:
VGLU3_HUMAN
Alternative names:
Solute carrier family 17 member 8
Alternative UPACC:
Q8NDX2; B3KXZ6; B7ZKV4; Q17RQ8
Background:
Vesicular glutamate transporter 3 (VGLUT3), encoded by the gene with the accession number Q8NDX2, is a multifunctional transporter. It is pivotal in transporting L-glutamate and various ions like chloride, sodium, and phosphate across membranes. Its primary role at the synaptic vesicle membrane is as an uniporter facilitating L-glutamate uptake into synaptic vesicles, crucial for neurotransmission in excitatory neural cells. Additionally, VGLUT3 functions as a chloride channel and, following exocytosis, as a symporter for Na(+) and phosphate, aiding in synaptic phosphate homeostasis.
Therapeutic significance:
The association of VGLUT3 with autosomal dominant deafness, 25 (DFNA25), underscores its clinical relevance. This condition, characterized by non-syndromic sensorineural hearing loss, highlights the therapeutic potential of targeting VGLUT3. Understanding the role of VGLUT3 could open doors to potential therapeutic strategies for hearing loss and other neurological conditions.